CR5.F CARDERO RESOURCE
- Market cap
- EUR 376M
- P/E
- -
- P/B
- 1.65x
- ROE
- -36.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CR5.F undervalued?
Graham numberThe Graham number of CARDERO RESOURCE cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CARDERO RESOURCE fundamental analysis
No fundamental analysis for CARDERO RESOURCE yet.
CARDERO RESOURCE stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CARDERO RESOURCE
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; an…
Full company profileCARDERO RESOURCE financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CARDERO RESOURCE annual financial statements (CHF; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -12.3M | -13.2M | -32.4M | -45.9M | -73.2M | -81.7M | -91.9M |
| EBITDA | - | - | -31.9M | -87.1M | -84.9M | -97.8M | -74.3M |
| Net Income | -14.9M | -18.6M | -38.7M | -88.8M | -85.8M | -99.0M | -76.1M |
| EPS | -0.45 | -0.57 | -1.18 | -2.42 | -1.96 | -1.71 | -1.37 |
| Balance Sheet | |||||||
| Total Assets | 16.4M | 58.0M | 37.1M | 114M | 120M | 236M | 232M |
| Total Liabilities | 60.0M | 119M | 135M | 20.6M | 47.0M | 39.9M | 23.6M |
| Shareholders' Equity | -43.7M | -61.0M | -98.0M | 93.7M | 73.4M | 196M | 209M |
| Cash & Short-term Investments | 4.95M | 46.3M | 19.8M | 38.3M | 27.7M | 81.3M | 66.3M |
| Cash Flow | |||||||
| Operating Cash Flow | -12.0M | -13.8M | -25.1M | -55.0M | -48.9M | -66.3M | -72.7M |
| Capital Expenditure | 19.0K | 28.0K | 3.55M | 48.0K | 230K | 1.39M | 28.0K |
| Free Cash Flow | -12.0M | -13.9M | -28.6M | -55.1M | -49.1M | -67.7M | -72.7M |
| Ratios | |||||||
| ROE | - | - | - | -94.7% | -116.9% | -50.5% | -36.4% |
| ROA | -90.8% | -32.0% | -104.4% | -77.7% | -71.3% | -41.9% | -32.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
CARDERO RESOURCE dividends
CARDERO RESOURCE has not paid dividends in the last 6 fiscal years.
Who owns CARDERO RESOURCE
- Insiders 3.52%
- Institutions 47.10%
- Public & others 49.38%
- Shares outstanding 55.7M
- Free float 51.6M
CARDERO RESOURCE company profile
- Company name
- CARDERO RESOURCE
- Ticker
- CR5.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Metals & Mining
- Employees
- 60
- Fiscal year end
- December
- Address
- Bahnhofstrasse 20, Zug, Switzerland, 6300
- Phone
- 41 41 711 3960
- Website
- oculis.com
About CARDERO RESOURCE
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
CARDERO RESOURCE management
9- Dr. Riad Sherif M.B.A., M.D.CEO & Director · born 1968
- Ms. Sylvia CheungChief Financial Officer · born 1975
- Ms. Gudrun Bachmann Ph.D.Chief Technology Officer
- Ms. Virginia R. DeanChief Human Resources Officer · born 1966
- Mr. Páll Ragnar JóhannessonChief Business Officer · born 1982
- Ms. Rebecca Weil Ph.D.Chief Commercial Officer
- Dr. Snehal Shah Pharm.D.President of Research & Development
- Dr. Sharon Klier M.D., M.P.H.Chief Development Officer
- Ms. Isabelle de Chambrier Pharm.D.Senior Vice President of Quality